Overall, women with more advanced MS disability had similar peripartum relapse activity as those with less disability, ...

So welcome to our Pharma Day 2025 here in London. It's good to see here full house. I was told we have, I think, a record attendance here on site, and we also have quite a high number, I think, of web ...

Some older adults with MS on disease-modifying therapies, mainly patients 60 and older, may be able to discontinue DMTs if ...

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may repair damage caused by the condition.

The McDonald criteria revisions provide a unified approach for diagnosing MS from pediatric to late-life presentations, said ...

Doctors in Cambridge believe they are “on the brink of a new class of treatments” for multiple sclerosis (MS) after a trial ...

Better diagnostics and more treatment options have modestly improved interstitial lung disease management in patients with ...

Patients with primary progressive MS more commonly exhibited delays in overall disability progression following treatment with ocrelizumab vs placebo.

Almost half of women with MS remain untreated during family planning, though ocrelizumab is the most commonly used DMT in this population.

Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating ...

Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will ...